<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Regeneron-Pharmaceuticals-US75886F1075">Regeneron Pharmaceuticals</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/04/13/3272182/0/en/Press-Release-Sanofi-and-Regeneron-s-Dupixent-approved-in-the-EU-as-the-first-targeted-medicine-to-treat-young-children-with-chronic-spontaneous-urticaria.html">Press Release: Sanofi and Regeneron&#39;s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria</a>
    </div>

      <div class="me-0 me-md-5">
        Sanofi and Regeneron&#39;s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Regeneron-Pharmaceuticals-US75886F1075">Regeneron Pharmaceuticals</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/04/13/3272191/0/en/Dupixent-dupilumab-Approved-in-the-EU-as-the-First-Targeted-Medicine-to-Treat-Young-Children-with-Chronic-Spontaneous-Urticaria-CSU.html">Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)</a>
    </div>

      <div class="me-0 me-md-5">
        Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly reduced urticaria activity compared with placebo in adults
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Regeneron-Pharmaceuticals-US75886F1075">Regeneron Pharmaceuticals</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/04/02/3267856/0/en/Regeneron-Collaborates-with-TriNetX-to-Access-De-Identified-Electronic-Health-Records-of-300-Million-Patients-to-Drive-Research-and-Product-Development-in-Life-Sciences-and-Digital.html">Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions</a>
    </div>

      <div class="me-0 me-md-5">
        Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX&#39;s industry-leading global network of electronic health record data
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Regeneron-Pharmaceuticals-US75886F1075">Regeneron Pharmaceuticals</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/trinetx-collaborates-with-regeneron-to-access-de-identified-electronic-health-records-of-300-million-patients-to-drive-research-and-product-development-in-life-sciences-and-digital-health-solutions-302733225.html">TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions</a>
    </div>

      <div class="me-0 me-md-5">
        Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX&#39;s industry-leading global network of electronic health record data Collaboration will expand Regeneron&#39;s world-leading genomic and proteomic EHR-linked database Growing database will continue to drive drug discovery and development and empower AI training algorithms to deliver digital health...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Regeneron-Pharmaceuticals-US75886F1075">Regeneron Pharmaceuticals</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-it-expects-avoid-new-us-pharma-tariffs-2026-04-02/">Regeneron says it expects to avoid new US pharma tariffs</a>
    </div>

      <div class="me-0 me-md-5">
        Drugmaker Regeneron said on Thursday it expects to be excluded ​from a list of pharmaceutical ‌companies that could face new tariffs from the U.S. government.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Regeneron-Pharmaceuticals-US75886F1075">Regeneron Pharmaceuticals</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/04/02/3267657/0/en/EYLEA-HD-aflibercept-Approved-by-FDA-as-First-and-Only-Injectable-Anti-VEGF-with-Dosing-Intervals-Up-to-5-Months-for-Wet-Age-related-Macular-Degeneration-wAMD-and-Diabetic-Macular-.html">EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)</a>
    </div>

      <div class="me-0 me-md-5">
        Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements with extended dosing intervals
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Regeneron-Pharmaceuticals-US75886F1075">Regeneron Pharmaceuticals</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">The Motley Fool</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.fool.com/investing/2026/03/30/regeneron-pharmaceuticals-a-strong-contender-in-th/">Regeneron Pharmaceuticals: A Strong Contender in the Biotech Arena</a>
    </div>

      <div class="me-0 me-md-5">
        Explore the exciting world of Regeneron Pharmaceuticals (REGN +1.57%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Regeneron-Pharmaceuticals-US75886F1075">Regeneron Pharmaceuticals</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">The Motley Fool</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.fool.com/investing/2026/03/27/is-regeneron-a-multimillionaire-maker-stock/">Is Regeneron a Multimillionaire-Maker Stock?</a>
    </div>

      <div class="me-0 me-md-5">
        The company is slowly recovering from recent headwinds. It could perform well through the next five to 10 years.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/en/news/Regeneron-Pharmaceuticals-US75886F1075/load_more?page=8">
      Show more News
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>